Danuglipron Dosage Calculator

Danuglipron is an oral tablet. No vials, no reconstitution, no bacteriostatic water. That's the entire practical appeal and why Pfizer invested in this program. The twice-daily dosing schedule matters. The half-life is roughly 6 to 8 hours, so missing a dose creates a 12 to 16 hour gap in receptor coverage. If you're reading about this compound for research context, the clinical doses ranged from 2.5 mg BID up to 200 mg BID depending on the trial and arm. The obesity trial targeted 40 to 200 mg BID. The T2D trial tested 2.5, 10, 40, 80, and 120 mg BID. Slow titration is the only tolerability strategy that showed any benefit. The 4-week titration schedule in Cohort 3 of the obesity trial [1] produced the best efficacy data (32 weeks at target dose) and better completion rates than faster titration arms. This drug is not available from compounding pharmacies. No FDA-approved reference drug exists, which means 503A and 503B pharmacies cannot legally compound it. Research chemical suppliers carry it for lab use only; those products are explicitly not for human consumption.